26,900 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Erste Asset Management GmbH

Erste Asset Management GmbH acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 26,900 shares of the company’s stock, valued at approximately $792,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in Denali Therapeutics by 879.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock valued at $48,000 after buying an additional 1,847 shares during the last quarter. Clarius Group LLC lifted its position in Denali Therapeutics by 4.5% during the second quarter. Clarius Group LLC now owns 409,995 shares of the company’s stock worth $9,520,000 after buying an additional 17,777 shares during the period. SG Americas Securities LLC raised its stake in Denali Therapeutics by 93.4% during the second quarter. SG Americas Securities LLC now owns 13,808 shares of the company’s stock worth $321,000 after purchasing an additional 6,667 shares during the period. Hamilton Lane Advisors LLC purchased a new stake in Denali Therapeutics during the second quarter valued at about $596,000. Finally, MONECO Advisors LLC purchased a new stake in Denali Therapeutics during the second quarter worth approximately $202,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $23.89 on Wednesday. Denali Therapeutics Inc. has a 52-week low of $14.56 and a 52-week high of $33.33. The business’s 50 day simple moving average is $27.07 and its 200 day simple moving average is $24.59. The firm has a market cap of $3.44 billion, a PE ratio of -8.66 and a beta of 1.35.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the company earned ($0.72) EPS. As a group, equities research analysts predict that Denali Therapeutics Inc. will post -2.69 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Denali Therapeutics in a report on Thursday, November 7th. Bank of America increased their price objective on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. JPMorgan Chase & Co. reduced their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald lowered shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $38.90.

Insider Buying and Selling

In other news, CEO Ryan J. Watts sold 40,000 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the sale, the chief executive officer now directly owns 235,807 shares of the company’s stock, valued at approximately $6,529,495.83. This represents a 14.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $29.03, for a total value of $870,900.00. Following the completion of the transaction, the director now directly owns 29,096 shares in the company, valued at approximately $844,656.88. This trade represents a 50.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 86,578 shares of company stock valued at $2,474,440 over the last quarter. 7.90% of the stock is owned by company insiders.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.